US Stock Market Move | Merck & Co., Inc. (MRK.US) and Moderna (MRNA.US) both saw their stock prices soar! The phase III trial of the personalized mRNA cancer vaccine was successful.

On Wednesday, Merck & Co., Inc. (MRK.US) rose nearly 10% to $148.44. Moderna (MRNA.US) surged over 113% to $134.51. In news, Moderna and Merck & Co., Inc. announced today that their jointly developed personalized mRNA cancer vaccine achieved positive results in a large Phase III clinical trial, marking the first successful Phase III trial of mRNA technology in the field of cancer treatment and representing a significant breakthrough in personalized immunotherapy in cancer treatment history. According to a joint statement from the two companies, the INTerpath-001 Phase III trial met its primary and key secondary endpointscompared to Merck & Co., Inc.'s immunotherapy drug Keytruda alone, the vaccine combined with Keytruda significantly reduced the risk of postoperative recurrence in melanoma patients and effectively inhibited tumor spread to distant organs. This is the first clinical regimen that has demonstrated superior efficacy over Keytruda monotherapy in adjuvant therapy for melanoma, while Keytruda had previously been the standard treatment option for this indication.